NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

For NWBO , the finalizing of the M and A games could not happen until the "out of the park home run " JAMA paper was published on 11/17/22. Discussions, no doubt, have been ongoing for a long time. These games are now at Olympic level and NWBO has been invited because of the JAMA paper . How many small biotechs have their phase 3 trail results published in a major ( household name) medical journal( JAMA, NEJM, Lancet, Nature , Science) ? The size of the check ($10 billion to $30 billion) that Big Pharma -Biotech needs to write to consummate a deal with NWBO is so big that no CEO would put his job at risk without his CSO signing off on the veracity of a scientific publication on the DC VAX L phase 3 trial , issued in a major medical journal. That said, what are the names of the major players for whom the DC VAX L platform ( applicable maybe to 90% of all solid tumors) would be a synergistic acquisition? Looks like any major Biotech Pharma with a high potential immunotherapy drug. Let's remember, Keytruda in 5 trials has proven that it ( 2023 revenues = $ 27 billion?) does not work in GBM, but it does when DC VAx L is added to the mix (

).



Some questions:

1) DID LP have an important meetings after the LL presentation on 11/20/22 ?


2) Is LARRY SMITH's estimate of 1 billion naked shorts correct ?

https://smithonstocks.com/could-there-have-been-hundreds-of-millions-or-even-more-than-a-billion-counterfeit-

shares-of-northwest-biotherapeutics-created-through-illegal-naked-shorting/


3) Do the nepharious ones have influence over the SEC ? The SEC has done nothing with its 2/22 short selling

reform proposal.( https://www.sec.gov/rules/proposed/2022/34-94313.pdf)


4) If there is a bid at $10 per NWBO share , would the 1 billion naked shorts require $20 billion to cover ?



5) On 11/17/22 we learned that the DC VAX L manuscript was accepted on August 27, 2022. Has announcing a




deal been delayed due to:


a) wanting to let Dr.Liau have the limelight at SNO ?


b) the CEO of the deal partner wanted to be sure the paper would be published.











Results A total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR?=?0.80; 98% CI, 0.00-0.94; P?=?.002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P?<?.001). Survival at 24 and 30 months after recurrence was 20.7% vs 9.6% and 11.1% vs 5.1%, respectively. Survival was improved in patients with nGBM with methylated MGMT receiving DCVax-L compared with external control patients (HR, 0.74; 98% CI, 0.55-1.00; P?=?.03).


N.B. At minute 8:50 ( https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 click into interview posted with the JAMA manuscript) Dr.Liau says, " patients characterized by methylated MGMT had MOS of 30.2 months versus 21.3 months ." Notice that this is not included in the "Results " section above. But is, later on in the paper. See next paragraph.



" Six prespecified subgroup analyses were conducted (Figure 2B and eFigure 1 in Supplement 2). Patients receiving DCVax-L had HRs less than 1 in all subgroups, and the difference was statistically significant for 4 of the 6 subgroups at the 95% confidence level, and for 3 of the 6 subgroups when multiplicity correction was applied. In patients with nGBM with methylated MGMT, mOS was 30.2 (95% CI, 23.7-33.9) months from randomization (33.0 months from surgery) in 90 patients receiving DCVax-L vs 21.3 (95% CI, 18.3-25.1) months in the 199 patients in the ECP (HR, 0.74; 95% CI, 0.55-1.00, P?=?.03)."


Bibliographic Miscellania:



https://www.sec.gov/ix?doc=/Archives/edgar/data/725363/000165495421013417/cvm_10k.htm (CVM has a $125 million market cap. They have never produced a a scientific publication on their phase 3 trial in a major medical journal .)



https://jamanetwork.com/journals/jama/fullarticle/2666504 (Stupp TTF paper 2017 launching NVCR to $ 23 billion market cap 7/21)

https://t.co/Wz0pzNOpN2 $nwbo @alphavestcap

— alphavestcapital.com (@alphavestcap) November 23, 2022

. (AZ CTO endorsement)

In the phase III externally controlled trial of autologous tumour lysate-loaded DC vaccination (DCVax-L) vs SoC for newly diagnosed or recurrent glioblastoma demonstrates promising median OS durations & meaningful increases in the tails of the OS curves: https://t.co/hJwfoQ6H0I

— NatureRevClinOncol (@NatRevClinOncol) November 22, 2022

. ( Nature Oncology endorsement of the NWBO JAMA paper)

https://www.nature.com/nrclinonc/



https://smithonstocks.com/explanation-of-how-adam-feuerstein-has-egregiously-misrepresented-the-results-of-the-phase-3-trial-of-dcvax-l/



https://nwbio.com/northwest-biotherapeutics-reports-positive-top-line-results-from-phase-3-trial-of-dcvax-l-for-glioblastoma/



https://www.sec.gov/ix?doc=/Archives/edgar/data/725363/000165495421013417/cvm_10k.htm


https://jamanetwork.com/journals/jama/fullarticle/2666504


https://edhub.ama-assn.org/jn-learning/audio-player/18738384?utm_source=twitter&utm_medium=social_jamaonc&utm_term=8215355596&utm_campaign=article_alert&linkId=190006813 (LL 18 minute interview which is attached to the JAMA paper)

https://en.wikipedia.org/wiki/Biotechnology


https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1672089627&Signature=hAJ8PhTQT~T7U24R3dq5aIuNxO2BOwv9Hpbgj8oXBl9FW9UwRtYjK5FJZ4NUYOQXr2R9Pv745J3Y0gsw-5P5i~3NF0LRULbaZvjXp5NZU6GeRuDXOFIFw4YGLOYfN0pNhqIYPfSZeZvdsNWQg10jzSqatxbznPnjgQBWJRXgh6E4rYT-M-m3GtBKxvV43zHfToEgTdLHOkgJFja7uq2ps4sLdfGOzPCQ9EOndFb8iKdoHIN4roUW9tucZgCLPwRqRuWzOxgkUNtJt2key2ylhyq1LISZjcZtCqXCDZzY28zMtn3w2hVO7FlDdDekEldEUqRwmXpXoIuEmSKJqBDrkw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA (NWBO's SAP)

https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext (Pazdur paper on external controls -1/9/22)


https://clinicaltrials.gov/ct2/show/NCT00045968?term=northwest+biotherapeutics&draw=2&rank=3

Bright Boy

Member Level
Re: None

Thursday, November 24, 2022 3:51:22 PM

Post#
538409
of 538409
My hunch is that next week is the kickoff for the "Vaccines for Cancers" Super Bowl with Linda Powers as the star QB of Team Northwest and the Dr. Liau experts filling the remaining 10 offensive positions guided by the world renowned JAMA "play selections" , Team Northwest will win in a massive blow out over Team SOC players using the aged playbook filled with over 400 plays that have failed to score a single point in 25 years!!!

Even with the AF/Statnews water boys, sideline team with their buckets of lies, Team SOC cannot be saved from a humiliating defeat!!!

I can see it now!! Cancer patients world wide lifted up on the winning shoulders of their DCVax-l personal vaccines waving flags and banners as they march in the victory parade along the main street of healthcare!!!!

Very exciting image ain't it !!!!!

Cheers and Happy Thanksgiving to all,

BB